rofecoxib has been researched along with Disease Models, Animal in 71 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the anti-angiogenesis mechanism of Rofecoxib and determine whether Rofecoxib can be a therapeutic agent for the prevention of retinal neovascularization using a model of retinopathy of prematurity (ROP)." | 7.81 | Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. ( Chen, L; Liu, NN; Sun, YZ; Zhao, N, 2015) |
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 7.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 7.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "Despite the apparent correlation between [(11)C]rofecoxib uptake and COX-2 distribution in healthy rats, [(11)C]rofecoxib could not unambiguously detect COX-2 overexpression in two rat models of inflammation." | 7.74 | Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. ( de Vries, EF; Dierckx, RA; Doorduin, J; van Waarde, A, 2008) |
| "Rofecoxib increased overall the arrhythmias including ventricular fibrillation (VF) during I/R." | 5.56 | Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. ( Baczkó, I; Baranyai, T; Brenner, GB; Ferdinandy, P; Gergely, TG; Giricz, Z; Görbe, A; Husti, Z; Kiss, B; Lázár, B; Makkos, A; Nagy, CT; Onódi, Z; Sághy, É; Sayour, NV; Schulz, R; Tóthfalusi, L; Varga, RS; Varró, A; Zádori, ZS, 2020) |
| "Curcumin is a yellow-colored plant polyphenol with a long history of medicinal use in ayurvedic, Chinese and Japanese medicine." | 5.35 | Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model. ( Chopra, K; Dhir, A; Kuhad, A; Nandal, S; Sharma, S, 2009) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "To explore the anti-angiogenesis mechanism of Rofecoxib and determine whether Rofecoxib can be a therapeutic agent for the prevention of retinal neovascularization using a model of retinopathy of prematurity (ROP)." | 3.81 | Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. ( Chen, L; Liu, NN; Sun, YZ; Zhao, N, 2015) |
| " This effect was prevented by rofecoxib treatment indicating the sensitivity of the model for pelvic pain related to peritonitis." | 3.80 | Use of dynamic weight bearing as a novel end-point for the assessment of abdominal pain in the LPS-induced peritonitis model in the rat. ( Gruen, M; Laux-Biehlmann, A; Nagel, J; Zollner, TM, 2014) |
| "The objective of this study was to determine whether a selective cyclooxygenase-2 inhibitor (rofecoxib) could alter the evolution of acute myocardial infarction after reperfusion." | 3.75 | Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. ( Carnieto, A; Chagas, AC; Dourado, PM; Luz, PL, 2009) |
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 3.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity." | 3.74 | Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008) |
| "Despite the apparent correlation between [(11)C]rofecoxib uptake and COX-2 distribution in healthy rats, [(11)C]rofecoxib could not unambiguously detect COX-2 overexpression in two rat models of inflammation." | 3.74 | Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. ( de Vries, EF; Dierckx, RA; Doorduin, J; van Waarde, A, 2008) |
| "The dose-response relation of S-methylisothiourea, rofecoxib, mefenamic acid, and their combination was studied in the late phase of formalin-induced pain in mice over the time spent in licking the hindpaw after formalin injection." | 3.74 | The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study. ( Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2008) |
| " In a chronic model, by acetic acid-induced gastric ulcers, COX-2 was expressed at 7 days and was also associated with PGE(2) increase." | 3.73 | COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. ( Alarcón de la Lastra, C; Bruseghini, L; Manuel Herrerias, J; Motilva, V; Sánchez-Fidalgo, S, 2005) |
| "Rofecoxib 15 or 30 mg/kg given for 6 days before MSU crystal injection into rat air pouches significantly suppressed the inflammation following injection of 10 mg crystals (p = 0." | 3.73 | Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch. ( Chen, LX; Clayburne, G; Nalbant, S; Schumacher, HR; Sieck, MS, 2005) |
| "In the WBN/Kob rat, chronic inflammatory changes and subsequent fibrosis can be inhibited by rofecoxib." | 3.73 | A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. ( Bimmler, D; Fortunato, F; Graf, R; Perren, A; Reding, T; Storni, F; Sun, LK, 2006) |
| " The aim of the present study was to examine the regulation of COX-2 in the rat SNI model and to evaluate the effectiveness of the selective COX-2 inhibitor rofecoxib in preventing neuropathic allodynia and hyperalgesia." | 3.72 | Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. ( Broom, DC; Geisslinger, G; Kohno, T; Samad, TA; Tegeder, I; Woolf, CJ, 2004) |
| "Rofecoxib is a selective cyclooxygenase (COX)-2 inhibitor approved for the treatment of pain and inflammation in rheumatoid and osteoarthritis." | 3.72 | Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. ( Geisslinger, G; Grösch, S; Niederberger, E; Schäfer, C; Seegel, M; Tegeder, I, 2003) |
| "Rofecoxib increased overall the arrhythmias including ventricular fibrillation (VF) during I/R." | 1.56 | Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. ( Baczkó, I; Baranyai, T; Brenner, GB; Ferdinandy, P; Gergely, TG; Giricz, Z; Görbe, A; Husti, Z; Kiss, B; Lázár, B; Makkos, A; Nagy, CT; Onódi, Z; Sághy, É; Sayour, NV; Schulz, R; Tóthfalusi, L; Varga, RS; Varró, A; Zádori, ZS, 2020) |
| " Compound 22 exhibited good pharmacokinetic properties and excellent oral bioavailability (F=78%, rat)." | 1.39 | Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. ( Banotai, C; Baum, H; Beidler, D; Bove, S; Braden, T; Cornicelli, J; Goodman, A; Gowan, R; Hicks, J; Lightle, S; Lu, XK; Miller, H; Ogden, A; Pandit, J; Plummer, MS; Roark, H; Sadagopan, N; Sanchez, B; Sarver, R; Shahripour, A; Shen, XQ; Skalitzky, DJ; Spessard, C; Stankovic, CJ; Welch, K; Whitehead, C, 2013) |
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Kainic acid (KA) was administrated in the hippocampus region of rat brain." | 1.37 | Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. ( Kumar, A; Pahwa, D; Prakash, A, 2011) |
| "Chronic pancreatitis is a severe inflammation of the pancreas associated with destruction of the parenchyma, fibrosis, and persistent abdominal pain." | 1.37 | COX-2 is not required for the development of murine chronic pancreatitis. ( Bain, M; Graf, R; Heikenwalder, M; Reding, T; Silva, A; Sonda, S; Weber, A, 2011) |
| "Curcumin is a yellow-colored plant polyphenol with a long history of medicinal use in ayurvedic, Chinese and Japanese medicine." | 1.35 | Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model. ( Chopra, K; Dhir, A; Kuhad, A; Nandal, S; Sharma, S, 2009) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| "p." | 1.35 | Rofecoxib potentiates the anticonvulsant effect of topiramate. ( Akula, KK; Dhir, A; Kulkarni, SK, 2008) |
| " Following dosing of CFA-injected rats with rofecoxib (Vioxx) or paracetamol, there was a significant decrease in the number of ipsilateral CGRP-IR small and medium DRG neurones in rofecoxib- but not paracetamol-treated rats." | 1.34 | Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. ( Bountra, C; Chessell, IP; Day, NC; Staton, PC; Wilson, AW, 2007) |
| " Mice were made physically dependent on alcohol by the chronic administration of ethanol (2 g/kg of 10% v/v), intragastrically, twice on day 1 and then once-daily on successive days for a total of 7 days." | 1.33 | Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. ( Dhir, A; Kulkarni, SK; Naidu, PS, 2005) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 108 Wistar rats allocated to: (1-4) NaCl 0." | 1.33 | Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. ( Beaulieu, P; Guindon, J, 2006) |
| "Treatment with rofecoxib significantly decreased these elevations except on day 4 of the study." | 1.33 | Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats. ( Can, B; Cengiz, M; Gencturk, S; Gocmen, E; Keskek, M; Kilic, M; Koc, M; Okten, RM, 2006) |
| " As prostaglandin E2 levels in spinal cord or in plasma were not reduced by Rofecoxib treatment, these results may suggest lack of sufficient bioavailability as the reason for the modest clinical changes observed." | 1.33 | Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. ( Azari, MF; Cheema, SS; Hirst, J; Le Grande, MR; Lopes, EC; Petratos, S; Profyris, C, 2005) |
| "Rofecoxib in lower doses had the same effect on adenomas (p < 0." | 1.33 | Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. ( Amengual Antich, I; Gamundí Gamundí, A; Ibarra de la Rosa, J; Noguera Aguilar, JF; Plaza Martínez, A; Pujol Tugores, JJ; Tortajada Collado, C, 2005) |
| " Swiss-Webster mice were dosed with celecoxib and rofecoxib and challenged with CT in ligated small intestinal loops, and intestinal segments from mice deficient in COX-1 and COX-2 were challenged with CT." | 1.32 | Role of cyclooxygenase enzymes in a murine model of experimental cholera. ( Boldogh, I; Gessell-Lee, DL; Olano, JP; Peterson, JW; Popov, VL, 2003) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "Carcinogenesis in Barrett's esophagus (BE) is associated with an increased expression of cyclooxygenase (COX) 2." | 1.31 | Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. ( Anderson, MA; Burgart, LJ; Buttar, NS; Krishnadath, KK; Leontovich, O; Lutzke, LS; Pacifico, RJ; Wang, KK; Westcott, JY, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.41) | 18.2507 |
| 2000's | 57 (80.28) | 29.6817 |
| 2010's | 10 (14.08) | 24.3611 |
| 2020's | 3 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SS | 1 |
| Noh, MS | 1 |
| Byun, YJ | 1 |
| Choi, JK | 1 |
| Kim, JY | 1 |
| Lim, KM | 1 |
| Ha, JY | 1 |
| Kim, JK | 1 |
| Lee, CH | 1 |
| Chung, S | 1 |
| Feixas, J | 1 |
| Jiménez, JM | 1 |
| Godessart, N | 1 |
| Puig, C | 1 |
| Soca, L | 1 |
| Crespo, MI | 1 |
| Swarbrick, ME | 1 |
| Beswick, PJ | 1 |
| Gleave, RJ | 1 |
| Green, RH | 1 |
| Bingham, S | 1 |
| Bountra, C | 3 |
| Carter, MC | 1 |
| Chambers, LJ | 1 |
| Chessell, IP | 3 |
| Clayton, NM | 1 |
| Collins, SD | 1 |
| Corfield, JA | 1 |
| Hartley, CD | 1 |
| Kleanthous, S | 1 |
| Lambeth, PF | 1 |
| Lucas, FS | 1 |
| Mathews, N | 1 |
| Naylor, A | 1 |
| Page, LW | 1 |
| Payne, JJ | 1 |
| Pegg, NA | 1 |
| Price, HS | 1 |
| Skidmore, J | 1 |
| Stevens, AJ | 1 |
| Stocker, R | 1 |
| Stratton, SC | 1 |
| Stuart, AJ | 1 |
| Wiseman, JO | 1 |
| Plummer, MS | 1 |
| Cornicelli, J | 1 |
| Roark, H | 1 |
| Skalitzky, DJ | 1 |
| Stankovic, CJ | 1 |
| Bove, S | 1 |
| Pandit, J | 1 |
| Goodman, A | 1 |
| Hicks, J | 1 |
| Shahripour, A | 1 |
| Beidler, D | 1 |
| Lu, XK | 1 |
| Sanchez, B | 1 |
| Whitehead, C | 1 |
| Sarver, R | 1 |
| Braden, T | 1 |
| Gowan, R | 1 |
| Shen, XQ | 1 |
| Welch, K | 1 |
| Ogden, A | 1 |
| Sadagopan, N | 1 |
| Baum, H | 1 |
| Miller, H | 1 |
| Banotai, C | 1 |
| Spessard, C | 1 |
| Lightle, S | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Brenner, GB | 2 |
| Makkos, A | 2 |
| Nagy, CT | 1 |
| Onódi, Z | 1 |
| Sayour, NV | 1 |
| Gergely, TG | 1 |
| Kiss, B | 1 |
| Görbe, A | 1 |
| Sághy, É | 1 |
| Zádori, ZS | 2 |
| Lázár, B | 2 |
| Baranyai, T | 1 |
| Varga, RS | 1 |
| Husti, Z | 1 |
| Varró, A | 1 |
| Tóthfalusi, L | 1 |
| Schulz, R | 1 |
| Baczkó, I | 1 |
| Giricz, Z | 2 |
| Ferdinandy, P | 2 |
| László, SB | 1 |
| Balogh, M | 1 |
| Al-Khrasani, M | 1 |
| Hutka, B | 1 |
| Mohammadzadeh, A | 1 |
| Kemény, Á | 1 |
| László, T | 1 |
| Scheich, B | 1 |
| Szabados, T | 1 |
| Kenyeres, É | 1 |
| Bencsik, P | 1 |
| Varga, ZV | 1 |
| Novák, J | 1 |
| Helyes, Z | 1 |
| Gyires, K | 1 |
| Kumar, A | 4 |
| Sharma, N | 1 |
| Mishra, J | 1 |
| Kalonia, H | 2 |
| Ji, B | 1 |
| Kumata, K | 1 |
| Onoe, H | 1 |
| Kaneko, H | 1 |
| Zhang, MR | 1 |
| Seki, C | 1 |
| Ono, M | 1 |
| Shukuri, M | 1 |
| Tokunaga, M | 1 |
| Minamihisamatsu, T | 1 |
| Suhara, T | 1 |
| Higuchi, M | 1 |
| Gruen, M | 1 |
| Laux-Biehlmann, A | 1 |
| Zollner, TM | 1 |
| Nagel, J | 1 |
| Liu, NN | 1 |
| Sun, YZ | 1 |
| Zhao, N | 1 |
| Chen, L | 1 |
| Nagai, N | 1 |
| Hoylaerts, MF | 1 |
| Gallacher, DJ | 2 |
| Lu, HR | 2 |
| Lijnen, HR | 3 |
| Angeby-Möller, K | 1 |
| Berge, OG | 1 |
| Hamers, FP | 1 |
| Van Hoef, B | 1 |
| Amaya, F | 1 |
| Samad, TA | 2 |
| Barrett, L | 1 |
| Broom, DC | 2 |
| Woolf, CJ | 2 |
| Marzoll, A | 1 |
| Nagy, N | 1 |
| Wördehoff, L | 1 |
| Dai, G | 1 |
| Fries, S | 1 |
| Lindner, V | 1 |
| Grosser, T | 1 |
| Fischer, JW | 1 |
| Carnieto, A | 1 |
| Dourado, PM | 1 |
| Luz, PL | 1 |
| Chagas, AC | 1 |
| Nandal, S | 1 |
| Dhir, A | 4 |
| Kuhad, A | 1 |
| Sharma, S | 1 |
| Chopra, K | 1 |
| Kumar, P | 2 |
| Nehru, B | 1 |
| Kumari, B | 1 |
| Silva, A | 1 |
| Weber, A | 1 |
| Bain, M | 1 |
| Reding, T | 2 |
| Heikenwalder, M | 1 |
| Sonda, S | 1 |
| Graf, R | 2 |
| Prakash, A | 1 |
| Pahwa, D | 1 |
| Alizzi, AM | 1 |
| Summers, P | 1 |
| Boon, VH | 1 |
| Tantiongco, JP | 1 |
| Thompson, T | 1 |
| Leslie, BJ | 1 |
| Williams, D | 1 |
| Steele, M | 1 |
| Bidstrup, BP | 1 |
| Diqer, AM | 1 |
| Bhardwaj, A | 1 |
| Batchu, SN | 1 |
| Kaur, J | 1 |
| Huang, Z | 1 |
| Seubert, JM | 1 |
| Knaus, EE | 1 |
| Hartner, A | 1 |
| Cordasic, N | 1 |
| Goppelt-Struebe, M | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Höcherl, K | 1 |
| Dreher, F | 1 |
| Kurtz, A | 1 |
| Bucher, M | 1 |
| Wilkinson-Berka, JL | 1 |
| Alousis, NS | 1 |
| Kelly, DJ | 1 |
| Gilbert, RE | 1 |
| Niederberger, E | 1 |
| Tegeder, I | 2 |
| Schäfer, C | 1 |
| Seegel, M | 1 |
| Grösch, S | 1 |
| Geisslinger, G | 2 |
| Candelario-Jalil, E | 1 |
| González-Falcón, A | 1 |
| García-Cabrera, M | 1 |
| Alvarez, D | 1 |
| Al-Dalain, S | 1 |
| Martínez, G | 1 |
| León, OS | 1 |
| Springer, JE | 1 |
| Hegazi, RA | 1 |
| Mady, HH | 1 |
| Melhem, MF | 1 |
| Sepulveda, AR | 1 |
| Mohi, M | 1 |
| Kandil, HM | 1 |
| Gessell-Lee, DL | 1 |
| Popov, VL | 1 |
| Boldogh, I | 1 |
| Olano, JP | 1 |
| Peterson, JW | 1 |
| Takeuchi, K | 2 |
| Miyazawa, T | 1 |
| Matsumoto, M | 1 |
| Hayashi, Y | 1 |
| Klivenyi, P | 1 |
| Gardian, G | 1 |
| Calingasan, NY | 1 |
| Yang, L | 1 |
| Beal, MF | 1 |
| Kohno, T | 1 |
| Vajja, BN | 1 |
| Juluri, S | 1 |
| Kumari, M | 1 |
| Kole, L | 1 |
| Chakrabarti, R | 1 |
| Joshi, VD | 1 |
| Kerins, C | 1 |
| Carlson, D | 1 |
| McIntosh, J | 1 |
| Bellinger, L | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Taxonera, C | 1 |
| Mendoza, JL | 1 |
| Noguera Aguilar, JF | 2 |
| Plaza Martínez, A | 2 |
| Amengual Antich, I | 2 |
| Morón Canis, JM | 1 |
| Tortajada Collado, C | 2 |
| Pujol Tugores, JJ | 2 |
| Vanchieri, C | 1 |
| Motilva, V | 1 |
| Alarcón de la Lastra, C | 1 |
| Bruseghini, L | 1 |
| Manuel Herrerias, J | 1 |
| Sánchez-Fidalgo, S | 1 |
| Hanson, CA | 1 |
| Weinhold, PS | 1 |
| Afshari, HM | 1 |
| Dahners, LE | 1 |
| Azari, MF | 1 |
| Profyris, C | 1 |
| Le Grande, MR | 1 |
| Lopes, EC | 1 |
| Hirst, J | 1 |
| Petratos, S | 1 |
| Cheema, SS | 1 |
| Perse, M | 1 |
| Zebic, A | 1 |
| Cerar, A | 1 |
| Nalbant, S | 1 |
| Chen, LX | 1 |
| Sieck, MS | 1 |
| Clayburne, G | 1 |
| Schumacher, HR | 1 |
| Wilson, AW | 2 |
| Medhurst, SJ | 1 |
| Dixon, CI | 1 |
| Bontoft, NC | 1 |
| Winyard, LA | 1 |
| Brackenborough, KT | 1 |
| De Alba, J | 1 |
| Clarke, CJ | 1 |
| Gunthorpe, MJ | 1 |
| Hicks, GA | 1 |
| McQueen, DS | 1 |
| Dubey, K | 1 |
| Balani, DK | 1 |
| Tripathi, CB | 1 |
| Singh, R | 1 |
| Bajaj, R | 1 |
| Pillai, KK | 1 |
| Ibarra de la Rosa, J | 1 |
| Gamundí Gamundí, A | 1 |
| Naidu, PS | 1 |
| Kulkarni, SK | 3 |
| Bimmler, D | 1 |
| Perren, A | 1 |
| Sun, LK | 1 |
| Fortunato, F | 1 |
| Storni, F | 1 |
| Guindon, J | 1 |
| Beaulieu, P | 1 |
| Kunz, T | 1 |
| Marklund, N | 1 |
| Hillered, L | 1 |
| Oliw, EH | 1 |
| Staton, PC | 1 |
| Day, NC | 1 |
| Bove, SE | 1 |
| Laemont, KD | 1 |
| Brooker, RM | 1 |
| Osborn, MN | 1 |
| Sanchez, BM | 1 |
| Guzman, RE | 1 |
| Hook, KE | 1 |
| Juneau, PL | 1 |
| Connor, JR | 1 |
| Kilgore, KS | 1 |
| Keskek, M | 1 |
| Gocmen, E | 1 |
| Kilic, M | 1 |
| Gencturk, S | 1 |
| Can, B | 1 |
| Cengiz, M | 1 |
| Okten, RM | 1 |
| Koc, M | 1 |
| Rotondo, S | 1 |
| Dell'Elba, G | 1 |
| Manarini, S | 1 |
| Cerletti, C | 1 |
| Evangelista, V | 1 |
| Dudhgaonkar, SP | 1 |
| Tandan, SK | 2 |
| Kumar, D | 2 |
| Naik, AK | 1 |
| Raviprakash, V | 1 |
| Yokota, A | 1 |
| Tanaka, A | 1 |
| Takahira, Y | 1 |
| Murnaghan, M | 1 |
| Li, G | 1 |
| Marsh, DR | 1 |
| Ni, J | 1 |
| Shu, YY | 1 |
| Zhu, YN | 1 |
| Fu, YF | 1 |
| Tang, W | 1 |
| Zhong, XG | 1 |
| Wang, H | 1 |
| Yang, YF | 1 |
| Ren, J | 1 |
| Wang, MW | 1 |
| Zuo, JP | 1 |
| Murphy, JO | 1 |
| Ravi, N | 1 |
| Byrne, PJ | 1 |
| McDonald, GS | 1 |
| Reynolds, JV | 1 |
| Karachalios, T | 1 |
| Boursinos, L | 1 |
| Poultsides, L | 1 |
| Khaldi, L | 1 |
| Malizos, KN | 1 |
| Murase, A | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Tonai-Kachi, H | 1 |
| Nakao, K | 1 |
| Takada, J | 1 |
| Akula, KK | 2 |
| de Vries, EF | 1 |
| Doorduin, J | 1 |
| Dierckx, RA | 1 |
| van Waarde, A | 1 |
| Bhat, AS | 1 |
| Krishna, V | 1 |
| Prakash, VR | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Sliwowski, Z | 1 |
| Drozdowicz, D | 1 |
| Stachura, J | 1 |
| Pajdo, R | 1 |
| Hahn, EG | 1 |
| Laudanno, OM | 1 |
| Cesolari, JA | 1 |
| Esnarriaga, J | 1 |
| Rista, L | 1 |
| Piombo, G | 1 |
| Maglione, C | 1 |
| Aramberry, LJ | 1 |
| Sambrano, JS | 1 |
| Godoy, A | 1 |
| Rocaspana, A | 1 |
| Buttar, NS | 1 |
| Wang, KK | 1 |
| Leontovich, O | 1 |
| Westcott, JY | 1 |
| Pacifico, RJ | 1 |
| Anderson, MA | 1 |
| Krishnadath, KK | 1 |
| Lutzke, LS | 1 |
| Burgart, LJ | 1 |
71 other studies available for rofecoxib and Disease Models, Animal
| Article | Year |
|---|---|
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.
Topics: Animals; Arthritis, Experimental; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygena | 2001 |
Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2001 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2009 |
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Topics: Analgesics; Animals; Azepines; Azirines; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cy | 2013 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Cardiotoxicity; Cell Survival; | 2020 |
Chronic treatment with rofecoxib but not ischemic preconditioning of the myocardium ameliorates early intestinal damage following cardiac ischemia/reperfusion injury in rats.
Topics: Animals; Biomarkers; Cardiotonic Agents; Coronary Occlusion; Coronary Vessels; Cyclooxygenase 2; Cyc | 2020 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model.
Topics: Animals; Antibodies; Brain; Brain Ischemia; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Disea | 2013 |
Use of dynamic weight bearing as a novel end-point for the assessment of abdominal pain in the LPS-induced peritonitis model in the rat.
Topics: Abdominal Pain; Analysis of Variance; Animals; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Mo | 2014 |
Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression.
Topics: Animals; Animals, Newborn; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2015 |
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone | 2008 |
Using the CatWalk method to assess weight-bearing and pain behaviour in walking rats with ankle joint monoarthritis induced by carrageenan: effects of morphine and rofecoxib.
Topics: Analgesics; Analgesics, Opioid; Animals; Ankle Joint; Anti-Inflammatory Agents; Arthralgia; Arthriti | 2008 |
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclooxygenase 2 Inhibitors; Dietary Fats; Disease Models, A | 2008 |
Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2008 |
Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion.
Topics: Analysis of Variance; Animals; Autonomic Fibers, Preganglionic; Behavior, Animal; Biophysics; Cycloo | 2009 |
Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carotid Arteries; Cyclooxygenase Inhibitors; Disease Mo | 2009 |
Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia.
Topics: Animals; Blood Pressure; Creatine Kinase, MB Form; Cyclooxygenase 2 Inhibitors; Disease Models, Anim | 2009 |
Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Curcumin; Cyclooxygenase 2 Inhibitors; Cy | 2009 |
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.
Topics: Animals; Anxiety; Catalase; Chronic Disease; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2010 |
COX-2 is not required for the development of murine chronic pancreatitis.
Topics: Actins; Age Factors; Animals; Ceruletide; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2011 |
Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Caffeic Acids; Cognition Disorders; Dise | 2011 |
Reduction of post-surgical pericardial adhesions using a pig model.
Topics: Animals; Biological Availability; Biomarkers; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Mod | 2012 |
Cardiovascular properties of a nitric oxide releasing rofecoxib analogue: beneficial anti-hypertensive activity and enhanced recovery in an ischemic reperfusion injury model.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cyclooxygenase 2; Disease Models, Animal; Drug Des | 2012 |
Role of macula densa cyclooxygenase-2 in renovascular hypertension.
Topics: Animals; Blood Pressure; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 2003 |
Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2002 |
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, A | 2003 |
Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Disease Models, Animal; Inflammat | 2003 |
Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.
Topics: Animals; Antioxidants; Biomarkers; Cell Count; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 | 2003 |
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal | 2003 |
Role of cyclooxygenase enzymes in a murine model of experimental cholera.
Topics: Aldehydes; Animals; Celecoxib; Cholera; Cholera Toxin; Cyclooxygenase 1; Cyclooxygenase 2; Disease M | 2003 |
Both selective COX-1 and COX-2 inhibitors aggravate gastric damage induced in rats by 2-deoxy-D-glucose. relation to gastric hypermotility and COX-2 expression.
Topics: Animals; Cyclooxygenase Inhibitors; Deoxyglucose; Disease Models, Animal; Dose-Response Relationship | 2003 |
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: Animals; Creatine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease | 2003 |
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain.
Topics: Animals; Behavior, Animal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2004 |
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cells, Cultured; Disease M | 2004 |
A role for cyclooxygenase II inhibitors in modulating temporomandibular joint inflammation from a meal pattern analysis perspective.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyc | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Colorectal cancer and Coxibs.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Colorectal Neoplasms; Cyclooxygenase Inhibitor | 2004 |
Influence of rofecoxib on experimental colonic carcinogenesis in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxyg | 2004 |
Vioxx withdrawal alarms cancer prevention researchers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyc | 2004 |
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
Topics: Acetic Acid; Acute Disease; Animals; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2005 |
The effect of analgesic agents on the healing rat medial collateral ligament.
Topics: Acetaminophen; Administration, Oral; Analgesics; Animals; Butorphanol; Collateral Ligaments; Disease | 2005 |
Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Cyclooxygenase Inhibitors; Dinoprostone; | 2005 |
Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer.
Topics: Administration, Oral; Animals; Biopsy, Needle; Colorectal Neoplasms; Disease Models, Animal; Drug Ad | 2005 |
Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
Topics: Animals; Arthritis, Gouty; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Inflammation; | 2005 |
An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models.
Topics: Animals; Arthritis; Chronic Disease; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Freund's A | 2006 |
Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroi | 2005 |
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2005 |
Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Animals; Behavior, Animal; Brain; Cyclooxygenase 2 Inhibito | 2005 |
A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis.
Topics: Animals; Cell Movement; Chemotactic Factors; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 In | 2006 |
Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain.
Topics: Animals; Arachidonic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, | 2006 |
Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat.
Topics: Animals; Brain Injuries; Cell Count; Cell Death; Cyclooxygenase 2 Inhibitors; Disease Models, Animal | 2006 |
Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Calcitonin Gene-Related P | 2007 |
Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia.
Topics: Amines; Analgesics; Animals; Arthralgia; Cyclohexanecarboxylic Acids; Cyclooxygenase 2 Inhibitors; D | 2006 |
Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats.
Topics: Acute Disease; Animals; Apoptosis; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Elect | 2006 |
Ameliorative effect of combined administration of inducible nitric oxide synthase inhibitor with cyclooxygenase-2 inhibitors in neuropathic pain in rats.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2007 |
Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Dinoproston | 2006 |
Nonsteroidal anti-inflammatory drug-induced fracture nonunion: an inhibition of angiogenesis?
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Fractures; Femur; Fracture Fix | 2006 |
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
Topics: Animals; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-R | 2007 |
Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux.
Topics: Animals; Antioxidants; Ascorbic Acid; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Resp | 2008 |
The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits.
Topics: Analysis of Variance; Animals; Bony Callus; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Fra | 2007 |
Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents; Benzamides; Benzoates; Cell Lin | 2008 |
Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism.
Topics: Adenine; Adenosine; Analysis of Variance; Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Anim | 2008 |
Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.
Topics: Animals; Brain; Carbon Radioisotopes; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, | 2008 |
The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study.
Topics: Animals; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2008 |
Rofecoxib potentiates the anticonvulsant effect of topiramate.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; | 2008 |
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 1999 |
[Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Mode | 2000 |
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2002 |